Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients
Simsek, Melek; Meijer, Berrie; Ramsoekh, Dewkoemar; Bouma, Gerd; van der Wouden, Egbert-Jan; den Hartog, Bert; de Vries, Annemarie C; Hoentjen, Frank; Dijkstra, Gerard; de Boer, Sybrand Y; Jansen, Jeroen M; van der Meulen, Andrea E; Beukers, Ruud; Brink, Menno A; Steinhauser, Toos; Oldenburg, Bas; Gilissen, Lennard P; Naber, Ton H; Verhagen, Marc A; de Boer, Nanne K H; Mulder, Chris J J; Dutch Initiative on Crohn and Colitis (ICC)
(2019) Clinical Gastroenterology and Hepatology, volume 17, issue 3, pp. 568 - 570
(Article)
Abstract
Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD). 1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and
... read more
the prognosis is unknown. 2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Gastroenterology, Hepatology
ISSN: 1542-3565
Publisher: W.B. Saunders Ltd
Note: Funding Information: Conflicts of interest These authors disclose the following: Annemarie C. de Vries has served as a speaker, member of advisory board, or consultant for Takeda, AbbVie, Tramedico, Dr Falk, and Jansen. Frank Hoentjen has served as a speaker, member of advisory board, or consultant for MSD, Takeda, Celltrion, Teva, Sandoz, Dr Falk, and Celgene. Gerard Dijkstra has received unrestricted research grants from AbbVie and Takeda; has served as a member of the advisory board for Mundipharma and Pharmacosmos; and has received speaker fees from Takeda and Janssen. Jeroen M. Jansen has served as a speaker, member of advisory board, or consultant for AbbVie, Janssen, Ferring, Pfizer, Takeda, and MSD. Bas Oldenburg has served as a speaker, member of advisory board, or consultant for AbbVie, Ferring, Janssen, MSD, Pfizer, and Takeda. Nanne K. H. de Boer has served as a speaker for AbbVie, Takeda, and MSD; has served as consultant and principal investigator for Takeda and TEVA Pharma BV; and has received research grants from Dr. Falk and Takeda. Chris J. J. Mulder has served a principal investigator for TEVA Pharma BV. The remaining authors disclose no conflicts. Publisher Copyright: © 2019 AGA Institute
(Peer reviewed)